The hilly landscape of the golf course at La Paloma Country Club, the first-year host of the Cologuard Classic by Exact Sciences, is one of a kind. It’s a rarity for PGA Tour Champions players to use ...

Abbott is getting into cancer testing with its $21 billion acquisition Exact Sciences, the maker of the game-changing colorectal cancer test Cologuard. Abbott markets well-known diagnostics for ...

North suburban-based Abbott Laboratories announced a $21 billion deal Thursday morning to acquire Exact Sciences, the maker of Cologuard — its largest acquisition in a decade. The deal will allow ...

The pending $23 billion sale of Madison-based Exact Sciences to health care giant Abbott centers on Exact Sciences' flagship product: colorectal cancer test Cologuard. Exact Sciences markets Cologuard ...

Bloomer announced, "We are raising total full year revenue to between $3.22 billion and $3.235 billion, an increase of $78 million at midpoint. This includes screening revenue between $2.51 billion ...

ASCs are increasingly at the forefront of colorectal cancer prevention efforts, particularly as new screening technologies gain traction. Following two FDA approvals last year, many ASCs are stepping ...

(NEXSTAR) — An unexpected delivery at your door may not always be an unwelcome surprise — just ask one Kentucky boy about the thousands of dollars worth of lollipops that arrived at his home earlier ...

In a troubling intersection of aggressive medical marketing and privacy concerns, thousands of Americans are receiving unrequested colon cancer screening tests at their doorsteps, a practice that has ...

Editor’s note: This story was updated to clarify recommendations for colorectal cancer screening. As a gastroenterologist, the most meaningful part of my job is preventing colorectal cancer by ...

Jeff Smith was dumbfounded when he received a colon cancer screening kit in the mail. The 68-year-old Minnesota man hadn't asked for the Cologuard test, and his doctor hadn't mentioned anything about ...